ABUS
Arbutus Biopharma Corporation NASDAQ Listed Jul 26, 2007$4.55
+2.71%
vs $4.43
Mkt Cap $898.8M
52w Low $3.04
73.3% of range
52w High $5.10
50d MA $4.36
200d MA $4.41
P/E (TTM)
-26.8x
EV/EBITDA
—
P/B
11.4x
Debt/Equity
0.1x
ROE
-43.8%
P/FCF
-22.0x
RSI (14)
49.60
ATR (14)
$0.16
Beta
0.74
50d MA
$4.36
200d MA
$4.41
Avg Volume
1.5M
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
701 Veterans Circle · Warminster, PA 18974 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | BMO | -0.03 | 0.88 | +3033.3% | 4.31 | +4.2% | +0.0% | +0.9% | -2.5% | -1.7% | +0.7% | — |
| Mar 23, 2026 | BMO | -0.04 | -0.01 | +71.3% | 4.42 | -2.3% | -2.5% | +5.1% | -1.8% | -3.6% | +0.2% | — |
| Nov 13, 2025 | BMO | -0.06 | -0.04 | +28.6% | 4.56 | -1.3% | -0.9% | +0.4% | -2.0% | -4.0% | -1.6% | — |
| Aug 6, 2025 | BMO | -0.02 | 0.01 | +150.0% | 3.47 | +1.7% | -2.0% | +0.0% | -1.5% | +1.5% | -0.9% | — |
| May 14, 2025 | BMO | -0.09 | -0.13 | -44.4% | 3.16 | -0.9% | -1.3% | -1.3% | +1.6% | +2.6% | -1.2% | — |
| Mar 27, 2025 | BMO | -0.08 | -0.07 | +12.5% | 3.27 | +0.0% | +7.0% | -0.3% | -0.3% | +0.9% | +0.0% | — |
| Nov 6, 2024 | BMO | -0.10 | -0.10 | +0.0% | 3.92 | +0.0% | -4.8% | +0.5% | -0.5% | -2.4% | +0.3% | — |
| Aug 1, 2024 | BMO | -0.10 | -0.11 | -10.0% | 3.81 | -3.1% | -1.8% | -3.2% | +0.0% | -3.0% | +2.6% | — |
| May 2, 2024 | BMO | -0.10 | -0.10 | +0.0% | 2.68 | +1.1% | +1.1% | +3.3% | +1.4% | +0.0% | +3.5% | — |
| Feb 29, 2024 | BMO | -0.12 | -0.12 | +0.0% | 2.80 | -0.7% | -0.4% | -2.9% | -1.5% | +2.6% | -1.5% | — |
| Nov 7, 2023 | BMO | -0.12 | -0.12 | +0.0% | 1.85 | +1.1% | +1.1% | -3.7% | -1.7% | +1.1% | +5.0% | — |
| Aug 3, 2023 | BMO | -0.12 | -0.10 | +16.7% | 2.06 | -0.5% | +3.9% | -1.9% | -3.3% | +0.0% | +1.5% | — |
| May 4, 2023 | AMC | -0.14 | -0.10 | +28.6% | 2.55 | +1.6% | +2.0% | +0.4% | +0.0% | +1.1% | -3.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 14 | Chardan Capital | Maintains | Buy → Buy | — | $4.56 | $4.50 | -1.3% | -0.9% | +0.4% | -2.0% | -4.0% | -1.6% |
| Aug 11 | Chardan Capital | Maintains | Buy → Buy | — | $3.40 | $3.40 | +0.0% | -1.5% | +1.5% | -0.9% | +0.0% | +0.0% |
| Mar 28 | Chardan Capital | Maintains | Buy → Buy | — | $3.27 | $3.27 | +0.0% | +7.0% | -0.3% | -0.3% | +0.9% | +0.0% |
| Jan 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.20 | $3.19 | -0.3% | +0.3% | +0.3% | +3.7% | -0.6% | +3.3% |
| Nov 20 | Chardan Capital | Maintains | Buy → Buy | — | $3.49 | $3.53 | +1.1% | -1.4% | +0.6% | +1.4% | -2.6% | -0.3% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.64 | $3.64 | +0.0% | -3.3% | -0.9% | -1.4% | +0.6% | +1.4% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.92 | $3.92 | +0.0% | -4.8% | +0.5% | -0.5% | -2.4% | +0.3% |
| Nov 6 | Chardan Capital | Maintains | Buy → Buy | — | $3.96 | $3.85 | -2.8% | -1.0% | -4.8% | +0.5% | -0.5% | -2.4% |
| Sep 5 | Jefferies | Maintains | Buy → Buy | — | $4.09 | $4.18 | +2.2% | +10.3% | +0.9% | -1.3% | +1.6% | +0.0% |
| Aug 2 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.81 | $3.69 | -3.1% | -1.8% | -3.2% | +0.0% | -3.0% | +2.6% |
| Jun 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.34 | $3.31 | -0.9% | -4.2% | -1.9% | +1.3% | +2.2% | -2.8% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.63 | $3.63 | +0.0% | -8.0% | -4.2% | -1.9% | +1.3% | +2.2% |
| Jun 5 | Chardan Capital | Maintains | Buy → Buy | — | $3.34 | $3.38 | +1.2% | +8.7% | -8.0% | -4.2% | -1.9% | +1.3% |
| May 3 | Chardan Capital | Maintains | Buy → Buy | — | $2.68 | $2.71 | +1.1% | +1.1% | +3.3% | +1.4% | +0.0% | +3.5% |
| Apr 4 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.92 | $2.93 | +0.3% | +2.7% | +4.0% | -1.0% | -2.6% | -1.0% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.80 | $2.78 | -0.7% | -0.4% | -2.9% | -1.5% | +2.6% | -1.5% |
| Mar 1 | Chardan Capital | Maintains | Buy → Buy | — | $2.80 | $2.78 | -0.7% | -0.4% | -2.9% | -1.5% | +2.6% | -1.5% |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.20 | $2.19 | -0.5% | -7.7% | +1.0% | +0.0% | -0.5% | -2.5% |
| Aug 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.06 | $2.05 | -0.5% | +3.9% | -1.9% | -3.3% | +0.0% | +1.5% |
| Aug 4 | Chardan Capital | Maintains | Buy → Buy | — | $2.06 | $2.05 | -0.5% | +3.9% | -1.9% | -3.3% | +0.0% | +1.5% |
| Jul 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.26 | $2.32 | +2.7% | +0.4% | +0.0% | +0.0% | -1.8% | +0.9% |
| Jul 6 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.26 | $2.25 | -0.4% | -1.3% | +1.3% | +0.0% | +0.4% | +0.0% |
| Jun 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.37 | $2.40 | +1.3% | +4.2% | -2.4% | -6.2% | -0.9% | +0.4% |
| Jun 22 | Chardan Capital | Maintains | Buy → Buy | — | $2.37 | $2.40 | +1.3% | +4.2% | -2.4% | -6.2% | -0.9% | +0.4% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.55 | $2.59 | +1.6% | +2.0% | +0.4% | +0.0% | +1.1% | -3.0% |
| Apr 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.51 | $2.52 | +0.4% | +0.0% | +0.4% | -1.6% | +1.2% | +1.6% |
| Apr 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.99 | $3.00 | +0.3% | -3.0% | -1.0% | +0.0% | +1.4% | -3.4% |
| Mar 29 | JMP Securities | Maintains | Market Outperform → Outperform | — | $3.00 | $3.02 | +0.7% | +3.3% | -2.6% | +0.3% | +1.0% | -2.3% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.99 | $3.02 | +1.0% | +1.0% | +0.3% | -2.6% | +0.3% | +1.4% |
| Mar 3 | Chardan Capital | Maintains | Buy → Buy | — | $2.81 | $2.80 | -0.4% | +1.8% | +0.7% | +1.7% | +0.7% | -4.1% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.81 | $2.80 | -0.4% | +1.8% | +0.7% | +1.7% | +0.7% | -4.1% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.44 | $2.50 | +2.5% | +1.6% | +3.2% | +3.1% | +5.7% | -3.2% |
| Jun 28 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.68 | $2.66 | -0.7% | -2.6% | +3.4% | +0.4% | +3.3% | +2.9% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.91 | $2.94 | +1.0% | -3.4% | +1.8% | +4.2% | +1.3% | +1.3% |
| Mar 4 | Chardan Capital | Maintains | Buy → Buy | — | $2.95 | $2.93 | -0.7% | -4.7% | +0.7% | +1.8% | +10.8% | -3.1% |
| Feb 2 | Jefferies | Upgrade | Hold → Buy | — | $2.92 | $3.13 | +7.2% | -1.0% | -4.5% | +9.4% | +3.3% | +1.6% |
| Nov 8 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.48 | $3.50 | +0.6% | +3.4% | -2.8% | -0.6% | -0.3% | +0.0% |
| Dec 17 | H.C. Wainwright | Maintains | Buy → Buy | — | $4.41 | $5.08 | +15.2% | +7.3% | -8.0% | -2.3% | -4.9% | +0.2% |
| Jul 24 | Baird | Downgrade | Outperform → Neutral | — | $6.20 | $7.98 | +28.7% | -20.0% | -9.9% | -10.1% | +0.5% | +6.4% |
| May 19 | Wedbush | Upgrade | Neutral → Outperform | — | $1.87 | $2.69 | +43.9% | +23.5% | +2.2% | -0.8% | -2.1% | -3.5% |
| Mar 27 | Baird | Maintains | Outperform → Outperform | — | $2.26 | $2.00 | -11.5% | -46.5% | -7.4% | -9.8% | +5.0% | -5.7% |
| Mar 6 | Chardan Capital | Upgrade | Neutral → Buy | — | $3.00 | $3.25 | +8.3% | -1.0% | -7.1% | +0.7% | -7.2% | -10.5% |
| Feb 20 | Baird | Maintains | Outperform → Outperform | — | $3.27 | $3.47 | +6.1% | +4.6% | -5.0% | -6.8% | -1.0% | -6.7% |
| Feb 5 | JMP Securities | Upgrade | Market Perform → Market Outperform | — | $2.81 | $3.25 | +15.7% | +15.3% | -1.2% | +1.6% | -1.5% | -4.1% |
| Jan 9 | B. Riley FBR | Maintains | Buy → Buy | — | $3.07 | $3.10 | +1.0% | -4.6% | +3.4% | -2.6% | +1.7% | +2.3% |
| Jan 9 | B. Riley Securities | Maintains | Buy → Buy | — | $3.07 | $3.10 | +1.0% | -4.6% | +3.4% | -2.6% | +1.7% | +2.3% |
| Oct 4 | Chardan Capital | Downgrade | Buy → Neutral | — | $1.43 | $1.01 | -29.4% | -28.7% | -9.8% | -3.3% | -2.2% | +2.3% |
| Oct 16 | B. Riley FBR | Upgrade | Neutral → Buy | — | $4.14 | $4.43 | +7.0% | +12.3% | +1.3% | -5.7% | -2.3% | +0.0% |
| Oct 16 | B. Riley Securities | Upgrade | Neutral → Buy | — | $4.14 | $4.43 | +7.0% | +12.3% | +1.3% | -5.7% | -2.3% | +0.0% |
| Oct 15 | Wedbush | Upgrade | Underperform → Neutral | — | $4.31 | $4.69 | +8.8% | -3.9% | +12.3% | +1.3% | -5.7% | -2.3% |
No insider trades available.
8-K · 5.02
!!! Very High
Arbutus Biopharma Corporation -- 8-K 5.02: Executive Change
May 27
8-K · 2.02
!! High
Arbutus Biopharma Corporation -- 8-K 2.02: Earnings Results
May 13
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
FDA Fast Track designation for imdusiran accelerates hepatitis B development timeline and potential market entry, improving commercialization prospects and de-risking the program for shareholders.
Apr 15
8-K
Unknown — 8-K Filing
Arbutus maintained disciplined spending and extended cash runway in Q4 2025, signaling management confidence in funding operations through key clinical milestones without dilutive financing.
Mar 23
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
Settlement with Moderna likely ends costly litigation risk for these biotech companies, potentially freeing resources for R&D and improving profit visibility going forward.
Mar 23
8-K · 8.01
!! High
Arbutus Biopharma Corporation -- 8-K 8.01: Material Event / Announcement
Arbutus Biopharma and Genevant entered a settlement agreement on March 3, 2026, resolving an unspecified dispute between the companies.
Mar 3
8-K · 8.01
!! High
Arbutus Biopharma Corporation -- 8-K 8.01: Material Event / Announcement
Arbutus Biopharma and licensee Genevant won a Delaware court ruling in their patent infringement litigation against Moderna, potentially securing damages for technology violations.
Feb 20
8-K · 8.01
!! High
Arbutus Biopharma Corporation -- 8-K 8.01: Material Event / Announcement
Arbutus Biopharma and its licensee Genevant won a Delaware court ruling against Moderna regarding patent infringement damages, potentially securing financial compensation for unauthorized use of their intellectual property.
Feb 6
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 53,405,552 | $257M | Added | Dec 2025 |
| 2 | Vanguard Capital Management Llc | 6,688,911 | $30M | New | Mar 2026 |
| 3 | Barclays Plc | 4,316,095 | $19M | Added | Mar 2026 |
| 4 | Adar1 Capital Management, Llc | 3,133,175 | $14M | New | Mar 2026 |
| 5 | Woodline Partners Lp | 2,010,172 | $9M | Reduced | Mar 2026 |
| 6 | Bank Of America Corp /de/ | 1,683,628 | $8M | Added | Mar 2026 |
| 7 | Vanguard Portfolio Management Llc | 1,392,024 | $6M | New | Mar 2026 |
| 8 | Northern Trust Corp | 1,277,859 | $6M | Added | Mar 2026 |
| 9 | Bank Of Montreal /can/ | 782,763 | $4M | Added | Mar 2026 |
| 10 | Hudson Bay Capital Management Lp | 675,000 | $3M | Reduced | Dec 2025 |
| 11 | Citadel Advisors Llc | 677,138 | $3M | Added | Mar 2026 |
| 12 | Citigroup Inc | 611,149 | $3M | Added | Dec 2025 |
| 13 | Millennium Management | 642,448 | $3M | New | Mar 2026 |
| 14 | Western Standard Llc | 521,587 | $2M | Added | Mar 2026 |
| 15 | Rangeley Capital, Llc | 500,000 | $2M | Reduced | Mar 2026 |
| 16 | Bank Of New York Mellon Corp | 379,373 | $2M | Reduced | Mar 2026 |
| 17 | Ubs Group Ag | 364,471 | $2M | Added | Mar 2026 |
| 18 | Ledgewood Wealth Advisors, Llc | 278,436 | $1M | — | Mar 2026 |
| 19 | Nuveen, Llc | 259,017 | $1M | — | Mar 2026 |
| 20 | Invesco Ltd. | 247,925 | $1M | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$898.8M
Enterprise Value
$783.7M
P/E (TTM)
-26.76x
Forward P/E
—
PEG Ratio
0.50x
P/B
11.38x
P/S
61.90x
P/FCF
-21.99x
EV/EBITDA
—
Shares Out
191.6M
Financials (TTM)
Revenue
$14.1M
Net Income
-$33.5M
EBITDA
-$26.7M
Free Cash Flow
-$39.6M
Op Cash Flow
-$39.6M
EPS Basic
$-0.17
EPS Diluted
$-0.17
EPS Forward
$-0.12
Gross Margin
97.4%
Op Margin
-192.1%
Net Margin
-237.9%
Balance Sheet
Total Assets
$94.6M
Total Liab.
$18.0M
Total Equity
$76.6M
Cash
$91.5M
LT Debt
$3.4M
Book Value/Sh
$0.40
Debt/Equity
0.05x
Current Ratio
15.73
Quick Ratio
15.73
Returns & Growth
ROE
-43.8%
ROA
-35.4%
ROIC
-30.3%
Rev Growth YoY
+128.2%
EPS Growth YoY
+55.3%
Price Returns
2W
+4.8%
1M
+8.6%
3M
-2.1%
6M
+3.4%
12M
+35.7%
Technicals
52W High
$5.10
52W Low
$3.04
50d MA
$4.36
200d MA
$4.41
RSI (14)
49.60
ATR (14)
$0.16
Beta
0.74
Avg Volume
1.5M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$8.50
High
$8.50
Low
$8.50
Median
$8.50
Data updated apr 24, 2026 10:20am
· Source: financialmodelingprep.com